Camurus AB ist ein forschungs- und entwicklungsorientiertes Pharmaunternehmen mit Sitz in Schweden, das sich auf die Entwicklung und Vermarktung von Spezialarzneimitteln konzentriert, die Patienten mit schweren und chronischen Krankheiten wie Opioidabhängigkeit, Schmerzen, Krebs, Akromegalie und neuroendokrinen Tumoren helfen. Das Unternehmen verfügt über ein diversifiziertes Forschungsportfolio, das fünf Produkte in der klinischen Erprobung und eine Reihe weiterer Produktkandidaten in der präklinischen Phase umfasst. Die Produktpipeline des Unternehmens besteht aus einer Mischung aus eigenen und Partnerprojekten in unterschiedlichen Entwicklungsphasen. Camurus AB ist die Muttergesellschaft der Gruppe, die vier juristische Personen umfasst, nämlich Camurus Inc, Cubosome Inc, Camurus Development AB und Bioimplant Scandinavia AB.
Q1:
www.camurus.com/media/press-releases/2022/...uary-march-2022/
"Camurus had a strong start of the year with results heading in the direction of long-term profitability."
Summary first quarter 2022
Total revenues amounted to SEK 220 (126) million, an increase of 75% (67% at CER1),
whereof product sales were SEK 202 (124) million, an increase of 63% (56% at CER)
Operating result was SEK 5 (-26) million, an increase of SEK 31 million
Cash position at the end of the quarter was SEK 400 (428) million
Full year 2022 outlook maintained
Market authorization for Buvidal® for the treatment of opioid dependence in Lebanon
New price and reimbursement approvals received for Buvidal in Belgium and Lebanon
Application for expanded market authorization for Buvidal to include chronic pain submitted to the Australian TGA and accepted for review
Dosing initiated in Camurus’ partner Rhythm Pharmaceutical’s Phase 3 study of setmelanotide weekly depot for the treatment of rare, genetic obesity disorders
Three Phase 3 studies for CAM2029 progressed in acromegaly and neuroendocrine tumors
Type C meeting held with the US Food and Drug Administration (FDA) aligning on patient reported outcomes (PROs) before initiating Phase 2/3 program of CAM2029 in polycystic liver disease
1) At constant exchange rates in January 2022.
Financial summary first quarter 2022
Total Revenue MSEK 220 (126)
- whereof product sales MSEK 202 (124)
OPEX MSEK 189 (137)
Operating result MSEK 5 (-26)
Result for the period MSEK -1 (-22)
Results per share, before and after dilution, of SEK -0.01 (-0.40)
Cash position MSEK 400 (428)
Fredrik Tiberg, President and CEO:
“Camurus had a strong start of the year with results heading in the direction of long-term profitability. We made significant progress in our R&D pipeline, strengthened our leading position in the treatment of opioid dependence and achieved positive operating results for the first time as a public company. Sales continued to grow and in addition there was a milestone payment from the partnership with Rhythm after dosing was initiated in a Phase 3 study in patients with rare obesity disorders. Our Phase 3 programs of CAM2029 for the treatment of acromegaly and neuroendocrine tumors progressed and preparations for the start of a new clinical study in patients with polycystic liver disease were completed.”
www.camurus.com/
www.finanzen.net/bilanz_guv/camurus_ab
Q1:
www.camurus.com/media/press-releases/2022/...uary-march-2022/
"Camurus had a strong start of the year with results heading in the direction of long-term profitability."
Summary first quarter 2022
Total revenues amounted to SEK 220 (126) million, an increase of 75% (67% at CER1),
whereof product sales were SEK 202 (124) million, an increase of 63% (56% at CER)
Operating result was SEK 5 (-26) million, an increase of SEK 31 million
Cash position at the end of the quarter was SEK 400 (428) million
Full year 2022 outlook maintained
Market authorization for Buvidal® for the treatment of opioid dependence in Lebanon
New price and reimbursement approvals received for Buvidal in Belgium and Lebanon
Application for expanded market authorization for Buvidal to include chronic pain submitted to the Australian TGA and accepted for review
Dosing initiated in Camurus’ partner Rhythm Pharmaceutical’s Phase 3 study of setmelanotide weekly depot for the treatment of rare, genetic obesity disorders
Three Phase 3 studies for CAM2029 progressed in acromegaly and neuroendocrine tumors
Type C meeting held with the US Food and Drug Administration (FDA) aligning on patient reported outcomes (PROs) before initiating Phase 2/3 program of CAM2029 in polycystic liver disease
1) At constant exchange rates in January 2022.
Financial summary first quarter 2022
Total Revenue MSEK 220 (126)
- whereof product sales MSEK 202 (124)
OPEX MSEK 189 (137)
Operating result MSEK 5 (-26)
Result for the period MSEK -1 (-22)
Results per share, before and after dilution, of SEK -0.01 (-0.40)
Cash position MSEK 400 (428)
Fredrik Tiberg, President and CEO:
“Camurus had a strong start of the year with results heading in the direction of long-term profitability. We made significant progress in our R&D pipeline, strengthened our leading position in the treatment of opioid dependence and achieved positive operating results for the first time as a public company. Sales continued to grow and in addition there was a milestone payment from the partnership with Rhythm after dosing was initiated in a Phase 3 study in patients with rare obesity disorders. Our Phase 3 programs of CAM2029 for the treatment of acromegaly and neuroendocrine tumors progressed and preparations for the start of a new clinical study in patients with polycystic liver disease were completed.”
www.camurus.com/
www.finanzen.net/bilanz_guv/camurus_ab
